BOIR.F Stock Overview
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Boiron SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €36.81 |
| 52 Week High | €53.50 |
| 52 Week Low | €35.25 |
| Beta | 0.47 |
| 1 Month Change | -4.32% |
| 3 Month Change | -20.36% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 59.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| BOIR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.0% | -1.8% | 0.3% |
| 1Y | n/a | 15.8% | 26.2% |
Return vs Industry: Insufficient data to determine how BOIR.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how BOIR.F performed against the US Market.
Price Volatility
| BOIR.F volatility | |
|---|---|
| BOIR.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BOIR.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BOIR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1932 | 2,813 | Valérie Lorentz-Poinsot | https://www.boiron.fr |
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain.
Boiron SA Fundamentals Summary
| BOIR.F fundamental statistics | |
|---|---|
| Market cap | US$634.72m |
| Earnings (TTM) | US$51.12m |
| Revenue (TTM) | US$555.47m |
12.4x
P/E Ratio1.1x
P/S RatioIs BOIR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOIR.F income statement (TTM) | |
|---|---|
| Revenue | €517.36m |
| Cost of Revenue | €135.11m |
| Gross Profit | €382.25m |
| Other Expenses | €334.63m |
| Earnings | €47.62m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Sep 11, 2024
| Earnings per share (EPS) | 2.74 |
| Gross Margin | 73.88% |
| Net Profit Margin | 9.20% |
| Debt/Equity Ratio | 0.5% |
How did BOIR.F perform over the long term?
See historical performance and comparison